Pharma Mar
Pharma Mar, officially known as Pharma Mar S.A., is a leading biopharmaceutical company headquartered in Madrid, Spain. Founded in 1986, the company has established itself as a pioneer in the research and development of marine-derived medicines, particularly in the oncology sector. With a strong focus on innovative therapies, Pharma Mar has made significant strides in the treatment of cancer, leveraging unique compounds sourced from the ocean. The company’s flagship products, including Yondelis and Aplidin, are distinguished by their novel mechanisms of action and have garnered attention in both clinical and commercial arenas. Pharma Mar's commitment to advancing cancer treatment has positioned it as a key player in the global biopharmaceutical landscape, with a robust pipeline and strategic partnerships enhancing its market presence.
DitchCarbon Score
How does Pharma Mar's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharma Mar's score of 19 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharma Mar's reported carbon emissions
Pharma Mar, headquartered in Spain, has set ambitious climate commitments to address its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established significant reduction targets. Pharma Mar aims to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2021 as the base year. Furthermore, the company is committed to measuring and reducing its Scope 3 emissions. In the long term, Pharma Mar has pledged to achieve a 90% reduction in total emissions across all scopes (1, 2, and 3) by 2050, again referencing 2021 as the baseline year. These targets have been validated through a streamlined process for small and medium-sized enterprises (SMEs) and align with the global goal of limiting temperature rise to 1.5°C. Pharma Mar's commitment to sustainability reflects its proactive approach in the pharmaceutical and biotechnology sector, positioning the company as a responsible player in combating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharma Mar is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
